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ABSTRACT
There have been dramatic advancements in the
treatment of chronic hepatitis C (HCV)
infection. This is largely due to the approval of
several direct-acting antiviral agents (DAAs)
from a variety of medication classes with
novel mechanisms of action. These therapies
are a welcomed advancement given their
improved efficacy and tolerability compared to
pegylated interferon and ribavirin (RBV)-based
regimens. These convenient, all-oral regimens
treat a variety of genotypes and often offer high
cure rates in a variety of HCV-infected
populations. While there are several benefits
associated with these therapies, there are also
notable shortcomings. Shortcomings include
diminished response or need for adjunctive
RBV in difficult-to-treat populations
(decompensated cirrhosis, active substance
abuse patients, advanced kidney disease, etc.),
activity against select genotypes, substantial
drug–drug interaction potential, and high cost.
Therefore, while current DAA-based therapies
have several favorable attributes, each also has
its limitations. The purpose of this review is to
(1) identify the characteristics of an ideal HCV
treatment regimen, (2) describe desirable
features of existing regimens, (3) summarize
limitations of existing regimens, and (4)
introduce promising emerging therapies. This
manuscript will serve as a guide for evaluating
the caliber of future HCV treatment regimens.
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INTRODUCTION
The emergence of direct-acting antiviral agents
(DAAs) has dramatically transformed the
chronic hepatitis C (HCV) treatment
landscape. Compared to the historic regimen
of pegylated interferon (PEG-IFN) and ribavirin
(RBV), DAAs exhibit both increased tolerability
and efficacy. Anticipated frequencies of
sustained virologic response (SVR12), defined
as an undetectable HCV RNA viral load at
12 weeks after completion of therapy, are
now[90% for many DAA-containing therapies
[1]. Achievement of SVR is associated with
numerous health benefits including regression
of fibrosis, a substantial reduction in the risk of
hepatocellular carcinoma, and a 90% reduction
in liver-related mortality [1]. Despite these
benefits, only about 5% of the estimated
2.2–3.2 million Americans infected with
chronic HCV (though nearly half are unaware
of their diagnosis) receive treatment [1, 2].
While current therapies are highly efficacious
and effective, many are extremely
patient-specific and treatment selection is
driven by viral genotype, presence of cirrhosis,
use of concomitant medications, and many
other considerations. They are also costly and
may not be accessible to all patients. Therefore,
while the approval of the DAAs is a welcomed
advancement compared to therapies containing
PEG-IFN and RBV, there are severable desirable
traits of an ‘‘ideal’’ HCV therapy that have yet to
be possessed by a single regimen. Emergence of
this highly-desirable therapy would mean a step
closer to HCV control and elimination in the
United States. The purpose of this review is to
(1) identify the characteristics of an ideal HCV
treatment regimen, (2) describe desirable
features of existing regimens, (3) summarize
limitations of existing regimens, and (4) present
promising emerging therapies. This review will
discuss ledipasvir/sofosbuvir (LDV/
SOF), paritaprevir/ritonavir/ombitasvir/dasabuvir
(PrOD), simeprevir/sofosbuvir (SIM/SOF),
daclatasvir/sofosbuvir (DAC/SOF), and
grazoprevir/elbasvir (GZR/EBR). Given its
similarity to PrOD, PrO will not be discussed [3].
This article is based on previously conducted
studies and does not involve any new studies of
human or animal subjects performed by any of
the authors.
EFFICACIOUS AND EFFECTIVE
While intuitive, an ideal HCV regimen should
be one that demonstrates high efficacy and
effectiveness. Cure of infection is defined as
achievement of sustained virologic response
(SVR), or undetectable HCV RNA viral load,
several weeks post-therapy completion.
Historically, cure was assessed at 6 months
(SVR24) after completion of up to 48 weeks of
therapy. Considering that assessment at
12 weeks post-therapy completion has shown
to be equally relevant [4], and that many
contemporary treatment regimens are only
8–12 weeks in duration, SVR12 is the current
standard [5].
Several available DAA-containing therapies
have demonstrated impressive frequencies of
SVR12, often greater than 90% and approaching
100%, in clinical trials [1]. SVR12 rates of
currently available regimens in clinical trials
are provided in Table 1. Though these findings
are important for market approval, trial
populations may not be fully representative of
patients who will receive the treatment in
practice. Therefore, an ideal treatment regimen
should demonstrate not only high efficacy but
also strong potential for real-world
effectiveness. Favorable outcomes should be
demonstrated across a spectrum of
HCV-infected patients, including those who
300 Infect Dis Ther (2016) 5:299–312
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are relatively healthy and treatment-naı¨ve
(‘‘uncomplicated’’) as well as those considered
more difficult-to-treat or ‘‘complicated’’ based
on individual history and comorbidities. These
patients may be treatment-experienced, with
high baseline viral loads and genetic variants
(e.g., Q80K in the context of
simeprevir-containing regimens), have various
coinfections such as human immunodeficiency
virus (HIV) or hepatitis B, and/or have advanced
liver disease (e.g., decompensated cirrhosis).
Historically, these patients have diminished
treatment responses and higher risks of
HCV-associated complications relative to
treatment-naı¨ve, HCV mono-infected patients
with no evidence of liver damage or cirrhosis
[1].
Consistent with expected outcomes from the
ideal treatment regimen, several available
therapies have demonstrated substantial
efficacy in difficult-to-treat patients, though
adjunctive RBV is often required. Cure rates
with DAA-based therapies, which often exceed
90%, are staggering compared to those
associated with PEG-IFN and RBV treatment,
which were approximately 17% for cirrhotic
patients, for example [6].
However, probability of cure remains highly
patient- and regimen-specific (e.g., presence of
the Q80K mutation in GT1a-infected,
treatment-experienced, cirrhotic patients is
associated with failure to SIM/SOF) [7, 8].
Several populations face limited treatment
options, including those with less common
GTs, renal disease, pregnant women,
post-transplant recipients, and previous
DAA-based therapy failures [1]. Additionally,
treatment would still prove successful in
populations unlikely to be included in trials or
large studies, including those with a recent
history of substance use, advanced age, and
psychiatric illness. Despite numerousT
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patient-specific challenges that complicate
effectiveness of available HCV therapies, the
ideal treatment regimen would result in high
probability of SVR12 consistently across all
HCV-infected populations without need for
adjunctive medications such as RBV.
SAFE
Non-Toxic
HCV treatment-associated toxicity was a
considerable patient care hurdle prior to 2013
when PEG-IFN and RBV continued to be
included in the mainstay of treatment. Given
its association with several adverse effects and
laboratory abnormalities, PEG-IFN plus RBV
required close safety monitoring. In some
cases, supplementary medications were
required to treat or manage HCV
treatment-associated adverse effects (e.g.,
epoetin alfa to treat drug-induced anemia). In
a contemporary setting, an ideal HCV treatment
should be tolerable and unlikely to cause
laboratory abnormalities. The latter is
important as frequent laboratory testing
during and potentially post-treatment are
inconvenient and costly. Lack of both
tolerability and overall treatment safety may
lead to possible patient harm, premature
discontinuation of therapy, and/or poor
adherence leading to unsuccessful cure.
Most contemporary HCV regimens
demonstrated high tolerability in clinical
trials, with infrequent therapy
discontinuations from serious adverse events.
For DAC/SOF and LDV/SOF, the most
commonly reported adverse events were
minor, including fatigue and headache [9, 10].
For SIM/SOF, a unique adverse effect is a variety
of dermatologic manifestations including rash
and pruritus. This typically occurs within
4 weeks of therapy initiation and may be due
to certain drug chemical properties (e.g., SIM
has a sulfa-like moiety) and/or photosensitivity
potential [7]. PrOD, though generally
well-tolerated in clinical studies, may cause
serious hepatic injury. Patients with advanced
liver disease appear to be particularly
susceptible, as described in a recently issued
FDA warning [3, 11]. Additionally, PrOD is
often co-administered with RBV, which can
cause hemolytic anemia. Considering the
toxicity potential of many currently available
HCV therapies, an ideal treatment regimen
would have a favorable toxicity profile with
minimal risk of serious adverse events.
Devoid of Drug–Drug Interactions
While adverse effects of each regimen should be
considered, it is also important to assess the
safety of anti-HCV agents when given
concomitantly with other medications.
Drug–drug interactions (DDIs) are of
substantial concern in the HCV-infected
population, given that treatment regimens
consist of multiple treatment medications for
patients that frequently have medically
managed comorbidities [12]. Many
interactions involve the cytochrome (CYP)
P450 isoenzyme system, including CYP3A4,
which metabolizes DAAs and several other
classes of medications [7]. Among the HCV
regimens, SIM is an inhibitor of intestinal
CYP3A4 and the ritonavir component of PrOD
is involved in the hepatic inhibition of CYP3A4
as well as several other CYP isoenzymes [7, 11].
GZR is a weak inhibitor of CYP3A4 and may be
implicated in fewer interactions [13]. LDV and
EBR are inhibitors of p-glycoprotein (PGP) and
breast cancer receptor protein (BCRP) [9, 13].
DAC is an inhibitor of PGP and organic anion
transporter protein (OATP) 1B1 [10].
304 Infect Dis Ther (2016) 5:299–312
DDIs involving each of the HCV regimens
and common classes of medications are
displayed in Table 2. HMG-CoA reductase
inhibitors (statins) are a popular medication
class subject to numerous DDIs with HCV
therapies, and management is agent-specific.
One of the most serious DDIs identified with
DAAs is coadministration of SOF and
amiodarone, which can result in severe
bradyarrhythmias. Coadministration is
contra-indicated and patients using
amiodarone should avoid SOF-containing
therapy [9, 14–16].
Within the HIV/HCV co-infected
population, DDIs with antiretrovirals are of
particular concern. Most protease inhibitors
(PIs) and non-nucleoside reverse transcriptase
inhibitors (NNRTIs) are problematic for GZR/
EBR, SIM/SOF and PrOD [7, 11, 13]. For LDV/
SOF, increased exposure (AUC) to tenofovir
disoproxil fumarate (TDF) is observed in HIV/
HCV co-infected patients using efavirenz or
protease-inhibitor containing regimens [9].
However, the degree of enhanced exposure
observed with efavirenz and TDF
coadministration with LDV/SOF is still within
the range of tenofovir AUC values in which
safety data exist. For regimens containing PIs
and TDF that are coadministered with LDV/
SOF, the upper bound of the confidence interval
slightly exceeds the range of tenofovir AUC
values in which safety data exist. The future
impact of the TDF interaction is unknown as
use of tenofovir alafenamide (TAF) becomes
more widespread. Dolutegravir and raltegravir
appear to be the safest options for
coadministration with HCV therapy. When
considering DDI management, a key
limitation of many available HCV therapies is
the coformulation of multiple antivirals in a
single product. Currently, dose personalization/
adjustment of individual agents associated with
an interaction or toxicity within a
co-formulated product is unfeasible. As
currently available HCV therapies pose
notable risks for potentially serious DDIs,
elimination of this potential would be an
important attribute of an ideal treatment
regimen.
CONVENIENT
An ideal HCV treatment regimen would have
convenient all oral administration. Reducing
pill burden and decreasing regimen complexity
are associated with improved clinical outcomes
in other therapeutic domains and may extend
to HCV [17–19]. In the HIV-infected
population, use of single tablet regimens
(STRs) is associated with improved medication
adherence to antiretroviral therapy and
decreased hospitalizations [20–22]. Similar
conclusions cannot be made in the context of
HCV infection, as studies have not yet been
performed comparing medication adherence to
single- versus multiple-tablet regimens and the
effect of number of tablets per day on achieving
SVR. In HCV, a single oral tablet formulation
dosed infrequently (e.g., daily) for a short
treatment duration would appear most
desirable, largely due to convenience.
However, the convenience of a single-tablet
regimen needs to be tempered with a discussion
of the relationship between non-adherence and
resistance. It is unclear if non-adherence to a
single-tablet regimen results in a higher
potential for development of drug resistance
than multiple-tablet regimens dosed multiple
times per day. A thorough understanding of the
pharmacokinetic/pharmacodynamics indices
associated with the development of resistance
will be imperative and predominantly
applicable to missing doses of medications
with short half-lives. This is an important area
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for evaluation in future studies as use of these
regimens becomes more widespread.
Regardless, strategies to improve adherence
should still be maximized, which include
patient education, frequent monitoring or
contact from clinicians, and patient devices to
enhance adherence (alarm clocks, pill boxes,
text reminders, etc.).
The convenience of HCV treatment has
improved dramatically. Historically, treatment
regimens consisted of daily or thrice weekly
injections used in combination with high
pill-burden oral medications that were dosed
multiple times a day for up to 48 weeks [1].
Today, several HCV treatments possess select
attributes of an ideal regimen. LDV/SOF and
GZR/EBR offer the convenience of single,
fixed-dose combination tablet regimens,
substantially decreasing treatment pill burden
[9, 13]. Dosing frequency has also improved
given that the majority of HCV treatment
regimens for GT1 infection are dosed once
daily [7, 9, 10, 13]. The exception to this is the
dasabuvir component of the PrOD regimen,
which is dosed twice daily [11]. While the
remaining regimens may be administered once
daily, some may require concomitant use of
twice daily RBV, particularly in patients with
cirrhosis and who have previously failed
therapy [7, 9–11, 13]. Unlike the traditional
interferon-based 48-week treatment course,
most DAA HCV regimens are 12 weeks in
duration. Post hoc findings from ION-3
suggest 8 weeks of LDV/SOF may be
appropriate for treatment-naı¨ve, non-cirrhotic,
GT1-infected patients with baseline HCV
RNA\6 million IU/mL [9, 23]. Similar
suggestions have been made for SIM/SOF in
GT1-infected patients with HCV RNA threshold
of 4 million IU/mL [8, 24]. Though not
prospectively validated or endorsed by
guidelines, these findings suggest theT
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possibility of shorter treatment courses without
compromised efficacy for select populations.
GZR/EBR plus RBV for 8 weeks may offer
another abbreviated treatment option, though
SVR rates were\90% [25]. Ideally, future
regimens will offer a short course of
conveniently administered therapy for all HCV
patient populations.
ACCESSIBLE AND AFFORDABLE
An ideal HCV regimen will be one that is
affordable and relatively easy to obtain for
patients from all socioeconomic backgrounds.
Many of these therapies are offered through
patient assistance programs to increase
accessibility and affordability for qualifying
individuals. However, many patients with
HCV infection face numerous barriers
hampering access to optimal therapy [26]. In
the US, barriers include high treatment costs,
lack of third party payer coverage or coverage
contingencies, requirement for prior
authorization approval, and therapy restriction
to only patients with severe infection. These
limitations and restrictions greatly complicate
patient access to appropriate HCV treatment.
This is particularly concerning given the
evidence that delays in therapy are associated
with an increased risk of adverse
HCV-associated outcomes [1].
The most widely discussed barrier is the high
treatment cost, which may not be affordable
out-of-pocket for the vast number of
HCV-infected patients that are uninsured or
underinsured [13]. While the true cost of these
medications to third party payers is largely
unknown due to proprietary contract pricing,
average wholesale pricing of many 12-week
courses of DAA treatments are in excess of
US$90,000 for the medication alone (i.e.
monitoring and clinic visit costs are not
included in this price) [10]. Currently, the
least expensive regimen is the newly-approved
GZR/EBR, costing approximately US$55,000
[11]. For those with prescription insurance,
high copayments or deductibles may still exist.
Additionally, while manufacturer-based patient
assistance programs exist for the DAAs, some
are associated with income restrictions or
manufacturer specific guidelines for treatment
[27].
If a patient does have prescription insurance,
various restrictions to DAA coverage may apply.
One restriction is prior authorization (PA),
whereby clinicians must provide written
justification to a third party payer as to why
the medication is necessary for the patient.
Additional patient requirements may include
urine toxicology panels, urine pregnancy tests,
or a consent form by which the patient pledges
adherence to medication therapy and follow-up
appointments. This added layer of approvals
imposed by some third-party payers requires
dedicated resources that may not be taken into
account by many cost-effectiveness models [28].
Restrictions may also apply for severity of
infection, which is commonly characterized by
the METAVIR score that assesses liver
necroinflammation and fibrosis. One study
indicated that among the 42 states with
known Medicaid restriction criteria for SOF,
74% limit treatment to patients with the
highest METAVIR scores of F3 or F4 [29].
There is limited evidence to support some of
the aforementioned requirements [1]. However,
with more widespread use of DAA-containing
regimens, there may be more evidence in the
future to support or refute HCV ‘‘stewardship,’’
such as rationing new agents for difficult
patients and inexpensive agents for less
complex patients. Notably, many of the
logistical issues described above are unique to
the US and may not be germane to other
308 Infect Dis Ther (2016) 5:299–312
geographic locales, or in the future with
movement towards universal healthcare
coverage. As more HCV-infected patients
obtain access to treatment, infection rates by
transmission may decline and subsequently
decrease the overall societal and financial
burden of HCV. An ideal regimen would be
affordable and accessible for all patients seeking
treatment.
HIGH BARRIER TO RESISTANCE
High efficacy demonstrated by several HCV
regimens means treatment success for many
patients. However, in the event of relapse or
treatment failure, an ideal therapy would
exhibit a high barrier to resistance with little
potential for cross-resistance with other agents.
Some regimens are affected by baseline NS5A
mutations. Among GT1A-infected patients
receiving 12 weeks of GZR/EBR, SVR was lower
among patients with at least one baseline NS5A
resistance-associated polymorphism at amino
acid positions 28, 30, 31 or 93 [3, 9]. Thus,
patients with GT1A infection initiating GZR/
EBR need to undergo NS5A testing. The
presence of any of these four polymorphisms
extends therapy from 12 to 16 weeks and
requires the addition of ribavirin [3, 9]. As the
use of NS5A inhibitors becomes more
ubiquitous and the issues of cross-resistance
and persistence of NS5A and NS3 mutations are
better understood, the impact of this test may
become applicable to other treatment regimens.
Findings may steer certain patient populations
from using these therapies. Cross-resistance
exists for some available agents including the
protease inhibitors, SIM and paritaprevir [7, 11].
SOF is advantageous in that it exhibits a high
barrier to resistance and, when used in
combination with other DAA agents, may still
be used successfully to overcome the presence
of baseline antiviral resistance-associated
variants (RAV) [9, 16]. LDV/SOF may offer a
promising treatment option for patients who
have failed a RBV-containing regimen or SIM/
SOF (though addition of RBV to LDV/SOF is
recommended for the latter); however, data are
limited [9]. PEG-IFN, though no longer a
component of most preferred regimens,
maintains activity in the setting of RAVs and
therefore remains a viable adjunctive option for
many treatment-experienced patients [1].
FUTURE DIRECTIONS
Several promising HCV treatment regimens
with ‘‘ideal’’ traits lie just over the horizon. A
novel NS5A inhibitor, velpatasvir (GS-5816), in
combination with SOF for 12 weeks, has
produced SVR12 rates[90% in patients with
GT1 through 6 in various stages of clinical study
[26, 30]. Cure was still achieved in most patients
exhibiting baseline genetic viral variants for
NS5A. While larger studies including more
difficult-to-treat populations are needed, such
as those with cirrhosis and history of treatment
failure, preliminary results are encouraging [27].
A pangenotypic option, if possessing other traits
of an ideal regimen, could increase accessibility
of treatment for all HCV-infected patients,
particularly those with currently limited
treatment options based on specific genotypes.
In addition to regimens offering
broad-spectrum genotypic activity, shorter
treatment durations are also being pursued.
Several 4- and 6-week combination therapy
regimens (2–3 agents) are being explored in
phase II studies that will hopefully add
additional highly efficacious, multigenotypic
therapies to the growing HCV treatment
armamentarium [30]. Though further beyond
Infect Dis Ther (2016) 5:299–312 309
the horizon, emergence of generic treatment
options will likely alter the treatment landscape
once again. A series of questions will arise
pertaining to cost-effectiveness of branded
single-tablet regimens versus less expensive
multiple-tablet regimens and the impact on
regimen adherence and ultimate treatment
success.
CONCLUSIONS
As the treatment landscape for chronic HCV
infection continues to rapidly evolve, the
characteristics associated with an ideal
regimen remain constant. An ideal regimen is
one that is efficacious in a variety of
populations, convenient, safe, accessible/
affordable, and has a high barrier to resistance.
Although significant progress has been made,
no commercially available regimen fully
achieves each of these desirable characteristics.
It is imperative for continued research and
development to achieve these goals to produce
dramatic reductions in HCV infection burden
globally.
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